First-pass extracted concept

engineered ocular and neurotropic AAV capsids

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Our study provides insight into state-of-the-art translational and drug-development considerations for engineered neurotropic and ocular capsids.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1comparative performance summarysupports2025Source 1DOI PubMed

Engineered capsids in the reviewed set exhibit enhanced tissue specificity, improved pharmacokinetics and pharmacodynamics, or reduced off-target effects compared with parent serotypes.

Claim 2review summarysupports2025Source 1DOI PubMed

Engineered neurotropic and ocular AAV capsids are being developed to enhance tissue and cell-specific targeting compared with naturally occurring serotypes.

Claim 3review summarysupports2025Source 1DOI PubMed

Natural AAV serotypes often lack specificity and efficiency, contributing to off-target effects and a low therapeutic index.